

Serge Koscielny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10403066/publications.pdf>

Version: 2024-02-01

40
papers

3,967
citations

236925

25
h-index

302126

39
g-index

40
all docs

40
docs citations

40
times ranked

5567
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Nonâ€“Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	3.0	25
2	Hyperprogressive Disease in Patients With Advanced Nonâ€“Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	7.1	567
3	Study of Inpatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography. <i>Investigative Radiology</i> , 2017, 52, 148-154.	6.2	25
4	WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11625-TPS11625.	1.6	1
5	Effect of nivolumab on tumor growth rate (TGR) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 481-481.	1.6	2
6	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 2402-2411.	13.7	157
7	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016, 7, 10767.	12.8	177
8	Cardiac Diseases Following Childhood Cancer Treatment. <i>Circulation</i> , 2016, 133, 31-38.	1.6	87
9	Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9034-9034.	1.6	11
10	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 3618-3626.	1.4	197
11	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>European Journal of Cancer</i> , 2015, 51, 2386-2395.	2.8	32
12	Statistical methods applied to omics data. <i>Current Opinion in Oncology</i> , 2014, 26, 576-583.	2.4	4
13	Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors. <i>Investigative Radiology</i> , 2014, 49, 794-800.	6.2	121
14	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. <i>Clinical Cancer Research</i> , 2014, 20, 246-252.	7.0	144
15	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. <i>European Urology</i> , 2014, 65, 713-720.	1.9	71
16	Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to LitiA're et al.). <i>European Journal of Cancer</i> , 2014, 50, 2887-2888.	2.8	1
17	Advanced Hepatocellular Carcinoma: Early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. <i>European Journal of Radiology</i> , 2013, 82, e205-e211.	2.6	88
18	BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e73993.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies. <i>Investigative Radiology</i> , 2012, 47, 711-716.	6.2	64
20	Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. <i>Investigational New Drugs</i> , 2012, 30, 765-771.	2.6	57
21	Multidimensionality of microarrays: Statistical challenges and (im)possible solutions. <i>Molecular Oncology</i> , 2011, 5, 190-196.	4.6	21
22	Tumour growth rates and RECIST criteria in early drug development. <i>European Journal of Cancer</i> , 2011, 47, 2512-2516.	2.8	73
23	Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results. <i>Radiology</i> , 2011, 258, 291-300.	7.3	201
24	Parallel progression of tumour and metastases. <i>Nature Reviews Cancer</i> , 2010, 10, 156-156.	28.4	19
25	Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter. <i>Clinical Cancer Research</i> , 2010, 16, 6180-6180.	7.0	2
26	Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic. <i>Science Translational Medicine</i> , 2010, 2, 14ps2.	12.4	97
27	Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography. <i>Clinical Cancer Research</i> , 2010, 16, 1216-1225.	7.0	170
28	On clonogenic tumour cells and metastasis-forming cells. <i>Nature Reviews Cancer</i> , 2008, 8, 990-990.	28.4	6
29	Critical review of microarray-based prognostic tests and trials in breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2008, 20, 47-50.	2.0	33
30	Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography. <i>Investigative Radiology</i> , 2008, 43, 100-111.	6.2	72
31	Prediction of cancer outcome with microarrays: a multiple random validation strategy. <i>Lancet, The</i> , 2005, 365, 488-492.	13.7	924
32	Validation of a New Method for Quantifying In Vivo Murine Tumor Necrosis by Sonography. <i>Investigative Radiology</i> , 2004, 39, 350-356.	6.2	29
33	Evaluation of Contrast-Enhanced Color Doppler Ultrasound for the Quantification of Angiogenesis In Vivo. <i>Investigative Radiology</i> , 2001, 36, 50-55.	6.2	94
34	The natural history of breast cancer and the link between local recurrence and distant metastases: implications for therapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2001, 6, 181-195.	0.6	5
35	Gallium Scan in the Evaluation of Post Chemotherapy Mediastinal Residual Masses of Aggressive Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 35, 579-586.	1.3	8
36	The link between local recurrence and distant metastases in human breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 11-24.	0.8	84

#	ARTICLE	IF	CITATIONS
37	Natural history of human breast cancer: Recent data and clinical implications. Breast Cancer Research and Treatment, 1991, 18, 125-140.	2.5	111
38	The natural history of breast cancer: Implications for a screening strategy. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1117-1120.	0.8	38
39	Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. International Journal of Cancer, 1989, 44, 17-22.	5.1	136
40	The Natural History of Human Breast Cancer: Implications for Patient Management. , 1987, , 333-347.		3